Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 122
Summary
- Conditions
- Cancer
- Cancer of Head and Neck
- Cancer, Advanced
- Cancer Metastatic
- Head and Neck Squamous Cell Carcinoma
- Oral Cancer
- Oropharyngeal Cancer
- Tumor Recurrence
- Oropharynx Cancer
- Tumor
- Oropharynx Cancer, Metastatic
- Oropharynx Cancer, Recurrent
- Oropharynx Cancer, Stage III
- Tumor Neck
- Tumor Metastasis
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This study is a prospective, multi-institutional, open-label, randomized phase II trial that will evaluate the efficacy of concurrent and adjuvant pembrolizumab with radiation therapy (RT) versus RT plus cisplatin in intermediate/high-riskp16-positive locoregionally advanced head and neck squamous c...
This study is a prospective, multi-institutional, open-label, randomized phase II trial that will evaluate the efficacy of concurrent and adjuvant pembrolizumab with radiation therapy (RT) versus RT plus cisplatin in intermediate/high-riskp16-positive locoregionally advanced head and neck squamous cell carcinoma (HNSCC). The primary endpoint is progression-free survival (PFS).
Tracking Information
- NCT #
- NCT03383094
- Collaborators
- Merck Sharp & Dohme Corp.
- Investigators
- Principal Investigator: Loren Mell, MD University of California, San Diego
Get Well Soon